Date Filed | Type | Description |
10/13/2023 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
10/13/2023 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
10/03/2023 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
10/03/2023 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
10/03/2023 |
SC 13D/A
| SILBER ALLAN C reports a 8.8% stake in POINT Biopharma Global Inc. |
10/03/2023 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
10/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data
Docs:
|
"AGREEMENT AND PLAN OF MERGER dated as of OCTOBER 2, 2023, among ELI LILLY AND COMPANY, YOSEMITE FALLS ACQUISITION CORPORATION and POINT BIOPHARMA GLOBAL INC.",
"TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT , dated as of October 2, 2023, is entered into by and among Eli Lilly and Company, an Indiana corporation , Yosemite Falls Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent , and the stockholders of POINT Biopharma Global Inc., a Delaware corporation , set forth on Schedule A hereto .  All terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement . WHEREAS, as of the date hereof, each Stockholder is the record or beneficial owner of the number of shares of Company Common Stock, Company PSUs and Company Stock Options set forth opposite such Stockholder’ s name on Schedule A ; WHEREAS...",
"TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT , dated as of October 2, 2023, is entered into by and among Eli Lilly and Company, an Indiana corporation , Yosemite Falls Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent , and the stockholders of POINT Biopharma Global Inc., a Delaware corporation , set forth on Schedule A hereto .  All terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement . WHEREAS, as of the date hereof, each Stockholder is the record or beneficial owner of the number of shares of Company Common Stock, Company PSUs and Company Stock Options set forth opposite such Stockholder’ s name on Schedule A ; WHEREAS...",
"Schedule A",
"Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies" |
|
08/14/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/14/2023 |
8-K
| Quarterly results |
08/03/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
03/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 8.7% stake in POINT Biopharma Global Inc. |
02/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
02/03/2023 |
SC 13G
| BlackRock Inc. reports a 5.1% stake in POINT Biopharma Global Inc. |
11/22/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
09/26/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in POINT BIOPHARMA GLOBAL INC. |
09/26/2022 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 5.4% stake in POINT Biopharma Global Inc. |
09/16/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 8.6% stake in POINT BIOPHARMA GLOBAL INC. |
09/14/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
09/14/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
09/13/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
09/13/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
09/12/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
09/06/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
08/29/2022 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 9.9% stake in POINT BIOPHARMA GLOBAL INC. |
08/12/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
07/12/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
07/11/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
|